Switch to:
Mindray Medical International Limited (NYSE:MR)
Research and Development
$127 Mil (TTM As of Dec. 2013)

This is the expense the company spent on research and development. Mindray Medical International Limited's research and development for the three months ended in Dec. 2013 was $41 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $127 Mil.


Definition

This is the expense the company spent on research and development.

Mindray Medical International Limited Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 26.328 (Mar. 2013 ) + 28.573 (Jun. 2013 ) + 31.573 (Sep. 2013 ) + 40.99 (Dec. 2013 ) = $127 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Mindray Medical International Limited Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Research & Development 713193059586082104127

Mindray Medical International Limited Quarterly Data

Sep11Dec11Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13
Research & Development 19262424233326293241
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide